scholarly journals Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial – CORRIGENDUM

BJPsych Open ◽  
2021 ◽  
Vol 7 (5) ◽  
Author(s):  
Minhan Dai ◽  
Yulu Wu ◽  
Yiguo Tang ◽  
Weihua Yue ◽  
Hao Yan ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Trajectory Analysis ◽  
Open Label ◽  
Multicentre Clinical Trial

scholarly journals Oral Nutritional Supplementation for the Dietary Management of Malnutrition in Cancer: Study Protocol of A Randomized, Open-Label, Multicentre Clinical Trial

2019 ◽  
Vol 4 (07) ◽  
Author(s):  
Edit Nadasi ◽  
Gellert Cseh
Keyword(s):  
Clinical Trial ◽  
Cancer Patients ◽  
Study Protocol ◽  
Negative Energy ◽  
Malignant Diseases ◽  
Open Label ◽  
Multicentre Clinical Trial ◽  
Patients With Cancer ◽  
Extra Energy ◽  
Oral Nutritional Supplements

In cancer, more than 30% of patients die due to cachexia and more than 50% of patients with cancer die with cachexia being present. Patients with cancer cachexia frequently develop a chronic negative energy and protein balance driven by a combination of reduced food intake and metabolic change. Several studies have already demonstrated the usefulness of oral nutritional supplements (ONS) in managing malnutrition of cancer patients. Though increased energy intake is very important in managing cancer-related malnutrition, the source of this extra energy and the presence of anti-inflammatory and immunonutritional components may also play an important role. Here we present the study protocol of a randomized, open-label, multicentre clinical trial aimed to determine whether an ONS composed according to the needs of patients with malignant diseases an ONS composed according to the needs of patients with malignant diseases is more effective than a general product in improving the nutritional status in cancer patients.

scholarly journals First-line eradication rates comparing two shortened non-bismuth quadruple regimens againstHelicobacter pylori: an open-label, randomized, multicentre clinical trial

2015 ◽  
Vol 70 (8) ◽  
pp. 2376-2381 ◽  
Author(s):  
Antonio Cuadrado-Lavín ◽  
J. Ramón Salcines-Caviedes ◽  
Ainhoa Diaz-Perez ◽  
Miguel F. Carrascosa ◽  
María Ochagavía ◽  
...  
Keyword(s):  
Clinical Trial ◽  
First Line ◽  
Open Label ◽  
Multicentre Clinical Trial

Oral Nutritional Supplementation for the Dietary Management of Malnutrition in Chronic Pulmonary Diseases: Study Protocol of a Randomized, Open-label, Multicentre Clinical Trial

2018 ◽  
Vol 4 (2) ◽  
pp. 262-266
Author(s):  
Edit Nadasi ◽  
Gellert Cseh
Keyword(s):  
Clinical Trial ◽  
Study Protocol ◽  
Nutritional Supplements ◽  
Pulmonary Diseases ◽  
Dietary Management ◽  
Open Label ◽  
Multicentre Clinical Trial ◽  
Pulmonary Functions ◽  
Oral Nutritional Supplements ◽  
Chronic Pulmonary Diseases

Disease-related malnutrition is frequent in patients with chronic pulmonary diseases. Though there is no doubt about the usefulness of Oral Nutritional Supplements (ONS) in managing malnutrition in such patients, only a handful of publications are available in the literature on clinical trials with ONS in this patient population. Since the digestion of macronutrients results in a strain on the respiratory functions in severe pulmonary diseases, the source of energy may also play a crucial role in the efficacy of nutrition with ONS in such patients. Here we present the study protocol of a randomized, open-label, multicentre clinical trial aimed to determine whether a new, condition-specific ONS (with a composition tailored to the needs of patients with decreased pulmonary functions) is more effective compared to a general ONS in improving the nutritional status in patients with compromised respiratory functions.

Intra-articular treatment with triamcinolone compared with triamcinolone with hyaluronate: A randomised open-label multicentre clinical trial in 80 lame horses

2015 ◽  
Vol 48 (2) ◽  
pp. 152-158 ◽  
Author(s):  
J. C. de Grauw ◽  
M. C. Visser-Meijer ◽  
F. Lashley ◽  
P. Meeus ◽  
P. R. van Weeren
Keyword(s):  
Clinical Trial ◽  
Open Label ◽  
Multicentre Clinical Trial

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial

2009 ◽  
Vol 10 (4-3) ◽  
pp. 710-718 ◽  
Author(s):  
Henrik Lublin ◽  
Hans-joachim Haug ◽  
Hannu Koponen ◽  
Thordur Sigmundsson ◽  
Stefan A. Kolb
Keyword(s):  
Clinical Trial ◽  
Chronic Schizophrenia ◽  
Open Label ◽  
Multicentre Clinical Trial

scholarly journals Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial

BJPsych Open ◽  
2020 ◽  
Vol 6 (6) ◽  
Author(s):  
Minhan Dai ◽  
Yulu Wu ◽  
Yiguo Tang ◽  
Weihua Yue ◽  
Hao Yan ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Treatment Response ◽  
Trajectory Analysis ◽  
Open Label ◽  
Longitudinal Dynamic ◽  
Early Treatment Response ◽  
Significant Difference ◽  
Trajectory Group ◽  
Treatment Responses ◽  
New Perspective

Background Understanding the patterns of treatment response is critical for the treatment of patients with schizophrenia; one way to achieve this is through using a longitudinal dynamic process study design. Aims This study aims to explore the response trajectory of antipsychotics and compare the treatment responses of seven different antipsychotics over 6 weeks in patients with schizoprenia (trial registration: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934). Method Data were collected from a multicentre, randomised open-label clinical trial. Patients were evaluated with the Positive and Negative Syndrome Scale (PANSS) at baseline and follow-up at weeks 2, 4 and 6. Trajectory groups were classified by the method of k-means cluster modelling for longitudinal data. Trajectory analyses were also employed for the seven antipsychotic groups. Results The early treatment response trajectories were classified into a high-trajectory group of better responders and a low-trajectory group of worse responders. The results of trajectory analysis showed differences compared with the classification method characterised by a 50% reduction in PANSS scores at week 6. A total of 349 patients were inconsistently grouped by the two methods, with a significant difference in the composition ratio of treatment response groups using these two methods (χ2 = 43.37, P < 0.001). There was no differential contribution of high- and low trajectories to different drugs (χ2 = 12.52, P = 0.051); olanzapine and risperidone, which had a larger proportion in the >50% reduction at week 6, performed better than aripiprazole, quetiapine, ziprasidone and perphenazine. Conclusions The trajectory analysis of treatment response to schizophrenia revealed two distinct trajectories. Comparing the treatment responses to different antipsychotics through longitudinal analysis may offer a new perspective for evaluating antipsychotics.

Sign in / Sign up

Export Citation Format

Share Document